Smoflipid
Brand Names: Smoflipid Generic
Methodology & AI Transparency ⓘ
Smoflipid Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Federal drug listing 63323-820 defines Smoflipid (manufactured/labeled by Fresenius Kabi USA, LLC) as a prescription-only intravenous-route lipid emulsion available in 6 g/100mL / 6 g/100mL Injection, Emulsion for individualized clinical regimens.
- 2 Real-world patient consensus: Tracked across 11 patient dosage logs with a 82% satisfaction benchmark (RxCUI RXN-63323820-2550).
- 3 Typical cash cost range: Dispensing cost comparison spans $60.34 mail/discount cash up to $147.83 uninsured retail (federal NADAC $1.2800).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Smoflipid: dizziness (7.2%), headache (5.9%), fatigue (4.5%).
Ask our AI Specialists anything about Smoflipid
Smoflipid Mechanism, CYP450 Pathways & DailyMed Monograph
Federal drug listing 63323-820 defines Smoflipid (manufactured/labeled by Fresenius Kabi USA, LLC) as a prescription-only intravenous-route lipid emulsion available in 6 g/100mL / 6 g/100mL Injection, Emulsion for individualized clinical regimens.
Clinical mechanism for Smoflipid (6 g/100mL / 6 g/100mL Injection, Emulsion, manufactured/labeled by Fresenius Kabi USA, LLC) centers on lipid emulsion target modulation following intravenous-route uptake, maintaining therapeutic plasma exposure across FDA-listed 63323-820 regimens.
Pharmacokinetic profiling of Smoflipid demonstrates an elimination half-life of Biphasic clearance with 5–18 hr terminal t½ under Smoflipid maintenance with Complete (~100%) parenteral systemic delivery for Smoflipid (6 g/100mL / 6 g/100mL Injection, Emulsion) systemic bioavailability; clearance proceeds via hepatic enzymatic processing and renal clearance proportional to creatinine clearance (smoflipid), reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after smoflipid administration.
Titration schedules for Smoflipid (6 g/100mL / 6 g/100mL Injection, Emulsion → 6 g/100mL) require excluding severe drug-induced hypersensitivity to smoflipid or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-07-01 for smoflipid; real-world patient logs highlight dizziness (7.2% of reports), headache (5.9% of reports), fatigue (4.5% of reports) alongside a 82.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Smoflipid (lipid emulsion).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Smoflipid dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Smoflipid or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-07-01 for Smoflipid
Logged Side-Effect Incidence (11 Reports)
Smoflipid Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Smoflipid)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on [Effectiveness and safety of two lipid emulsions for parenteral nutrition in There were no statistically significant differences in the occurrence of adverse effects either. Nutricion hospitalaria • 2021-02-23 • Phase III Randomized Trial | N = 73 | 82/100 | PMID 33319565 ↗ |
Smoflipid Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.2800/unit (~$38.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $147.83 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $60.34 / mo | View logs ↓ |
Smoflipid Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Smoflipid RxNorm Concept ID | RXN-63323820-2550 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.2800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $147.83 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $60.34 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 82.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Smoflipid Patient Community, Cohort Filters & Dosage Logs
Cross-verified Smoflipid (lipid emulsion) monograph synthesizing RxNorm RXN-63323820-2550, openFDA FAERS signals, and $60.34–$147.83 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Smoflipid community threads and patient logs by age, biological sex, dosage, and treatment duration.